Japanese drugmaker Eisai and US-based Biogen have been working together on advancing research in the space of Alzheimer’s for nearly a decade. Finally, the FDA, granted the fruits of that labor, Leqembi, its blessing for intravenous use. This marks the first approved treatment that can slow the progression of Alzheimer’s.

  • june@lemmy.world
    link
    fedilink
    English
    arrow-up
    28
    arrow-down
    1
    ·
    1 year ago

    This is the first time I’ve opened a post on Lemmy and seen such a valuable response. Thanks for being here and taking the time to post this. Super interesting and informative stuff.

    My ex wife’s dad is in the middle stages of early onset dementia (he’s in his mid-60’s) and I’m thinking it’s a bit too late for this to be helpful. But seeing this progress gives me hope for my ex-wife and her brother who both have very high risk of dementia (grandma, their dad, and their uncle all suffer(ed) from it, dad and uncle are both in similar stages with dad a couple years behind uncle… really sad shit).

    I really hope we get this figured out in the next 20 years.